Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 674 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Routes to a healthier shopping journey – how your supermarket environment... April 19, 2023 What Should People With Cancer Know About Alkaline Water? February 16, 2021 Your questions on our research strategy March 29, 2022 Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2023:... Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced... Ovarian cancer screening trial did not save lives This Common Antibiotic May Help Support Immune System in Cancer Patients...
